EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study

Alexander T Cohen, Christopher Wallenhorst iD, Marcella Rivera, Cihan Ay, Bernhard Schaefer, Khaled Abdelgawwad, George Psaroudakis, Gunnar Brobert, Anders Ekbom, Agnes Y Y Lee, Alok A Khorana iD, Cecilia Becattini und 3 weitere

Thrombosis and Haemostasis · 01.03.2025 · 125 (03) · 265-277

DOI: 10.1055/a-2259-0662 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2025. Verfasst von Alexander T Cohen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Rivaroxaban, Heparin, Low-Molecular-Weight, Venous Thromboembolism, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In most patients with cancer-associated venous thromboembolism (CT), essentially those not at high risk of bleeding, guidelines recommend treatment with direct oral anticoagulants as an alternative to low-molecular-weight heparins (LMWHs). Population-based studies comparing these therapies are scarce.

Objectives

To compare the risk of venous thromboembolism (VTE) recurrences, significant bleeding, and all-cause mortality in patients with CT receiving rivaroxaban or LMWHs. Patients/Methods Using UK Clinical Practice Research Datalink data from 2013 to 2020, we generated a cohort of patients with first CT treated initially with either rivaroxaban or LMWH. Patients were observed 12 months for VTE recurrences, significant bleeds (major bleeds or clinically relevant nonmajor bleeding requiring hospitalization), and all-cause mortality. Overlap weighted sub-distribution hazard ratios (SHRs) compared rivaroxaban with LMWH in an intention-to-treat analysis.

Results

The cohort consisted of 2,259 patients with first CT, 314 receiving rivaroxaban, and 1,945 LMWH, mean age 72.4 and 66.9 years, respectively. In the 12-month observational period, 184 person-years following rivaroxaban and 1,057 following LMWH, 10 and 66 incident recurrent VTE events, 20 and 102 significant bleeds, and 10 and 133 deaths were observed in rivaroxaban and LMWH users, respectively. The weighted SHR at 12 months for VTE recurrences in rivaroxaban compared with LMWH were 0.80 (0.37–1.73); for significant bleeds 1.01 (0.57–1.81); and for all-cause mortality 0.49 (0.23–1.06).

Conclusion

Patients with CT, not at high risk of bleeding, treated with either rivaroxaban or LMWH have comparable effectiveness and safety outcomes. This supports the recommendation that rivaroxaban is a reasonable alternative to LMWH for the treatment of CT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanHeparin, Low-Molecular-WeightVenous ThromboembolismNeoplasmsFactor Xa InhibitorsAnticoagulantsHumansAgedMaleFemaleHemorrhageMiddle AgedUnited KingdomTreatment OutcomeRecurrenceAged, 80 and overRisk Factors

Substanzen

RivaroxabanHeparin, Low-Molecular-WeightFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom.
  • Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt am Main, Germany.
  • Bayer AG, Berlin, Germany at the time of study conduct, currently affiliated to Janssen Research and Development, Barcelona, Spain.
  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Bayer AG, Berlin, Germany.
  • Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

ORCID-Profile: Christopher Wallenhorst, Alok A Khorana, Craig I Coleman, Carlos Martinez

Förderung

  • Bayer

Zitieren

APA

Cohen, A. T., Wallenhorst, C., Rivera, M., Ay, C., Schaefer, B., Abdelgawwad, K., Psaroudakis, G., Brobert, G., Ekbom, A., Lee, A. Y. Y., Khorana, A. A., Becattini, C., Carrier, M., Coleman, C. I., & Martinez, C. (2025). Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study. Thrombosis and Haemostasis, 125(03), 265-277. https://doi.org/10.1055/a-2259-0662

Vancouver

Cohen AT, Wallenhorst C, Rivera M, Ay C, Schaefer B, Abdelgawwad K, et al. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study. Thrombosis and Haemostasis. 2025;125(03):265-277. doi:10.1055/a-2259-0662

BibTeX
@article{Cohen2025,
  author = {Cohen, Alexander T and Wallenhorst, Christopher and Rivera, Marcella and Ay, Cihan and Schaefer, Bernhard and Abdelgawwad, Khaled and Psaroudakis, George and Brobert, Gunnar and Ekbom, Anders and Lee, Agnes Y Y and Khorana, Alok A and Becattini, Cecilia and Carrier, Marc and Coleman, Craig I and Martinez, Carlos},
  title = {Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {03},
  pages = {265--277},
  doi = {10.1055/a-2259-0662}
}
Kostenlos starten →